American Heart Journal
Volume 147, Issue 2 , Pages 197-199 , February 2004

Restenosis: are the implications changing?

  • Jason H Cole, MD

      Affiliations

    • Emory University, Atlanta, Ga, USA
    • ,
  • William S Weintraub, MD

      Affiliations

    • Emory University, Atlanta, Ga, USA
    • Corresponding Author InformationReprint requests: William S. Weintraub, MD, Professor of Medicine, Emory University, 1256 Briarcliff Road, Suite 1N, Atlanta, GA 30306, USA.

References 

  1. Kimura T, Yokoi H, Nakagawa Y, et al.  Three-year follow-up after implantation of metallic coronary stents. N Engl J Med. 1996;334:561–566
  2. Fischman DL, Leon MB, Baim DS, et al.  A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501
  3. Serruys P, de Jaegere P, Kiemeneij F, et al.  A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease in patients with coronary artery disease. N Engl J Med. 1994;331:489–495
  4. Lowe HC, Oesterle SN, Khachigian LM, et al.  Coronary in-stent restenosis (current status and future strategies). J Am Coll Cardiol. 2002;39:183–193
  5. Kastrati A, Schömig A, Elezi S, et al.  Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30:1428–1436
  6. Virmani R, Farb A. Pathology of in-stent restenosis. Curr Opin Lipidol. 1999;10:499–506
  7. Leon MB, Teirstein PS, Moses JW, et al.  Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;334:250–256
  8. Sousa JE, Costa MA, Abizaid AC, et al.  Sustained suppression of neointimal proliferation by sirolimus-eluting stents (one-year angiographic and intravascular ultrasound follow-up). Circulation. 2001;104:2007–2011
  9. Weintraub WS, Ghazzal ZM, Douglas JS, et al.  Long-term clinical follow-up in patients with angiographic restudy after successful angioplasty. Circulation. 1993;87:831–840
  10. Kereiakes D. Hippocrates revisited (the evidence for drug-eluting stents). Circulation. 2003;107:3012–3014
  11. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents (cost versus clinical benefit). Circulation. 2003;107:3003–3007
  12. Ruygrok PN, Webster MW, deValk V, et al.  Clinical and angiographic factors associated with asymptomatic restenosis after percutaneous coronary intervention. Circulation. 2001;104:2289–2294
  13. Zellweger MJ, Weinbaker M, Zutter AW, et al.  Long-term outcome of patients with silent versus symptomatic ischemia six months after percutaneous coronary intervention and stenting. J Am Coll Cardiol. 2003;42:33–40
  14. Schühlen H, Kastrati A, Mehilli J, et al. Restenosis detected by routine angiographic follow-up and late mortality after coronary stent placement. Am Heart J 2004;147:317–22
  15. Surruys PWJC, de Feyter P, Macaya C, et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention (a randomized controlled trial). JAMA. 2002;287:3215–3222
  16. Sopko G. Preventing cardiac events and restenosis after percutaneous intervention. [editorial] JAMA. 2002;287:3259–3261

PII: S0002-8703(03)00705-1

doi: 10.1016/j.ahj.2003.10.001

American Heart Journal
Volume 147, Issue 2 , Pages 197-199 , February 2004

Article Tools